Skip to main content
GALT
NASDAQ Life Sciences

Galectin 10-Q: Going Concern Warning, Cash Funds Operations Only Through June 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.1
Mkt Cap
$307.591M
52W Low
$2.025
52W High
$7.13
52W Position info
53% above low
Off High info
57% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GALT sits 53% above its 52-week low of $2.025.

Summary

Galectin's Q3 2026 10-Q flags substantial doubt about going concern, with cash and the chairman's line of credit funding operations only through June 2027. The July conversion of $105.8M of chairman debt into 34.4M shares sharply reduced liabilities but left the company dependent on new financing.


Key Events · Earnings and Guidance · GALT

  • Going Concern Warning Disclosed

    Management states substantial doubt about the ability to continue as a going concern for 12 months from issuance, with $11.7M of unrestricted cash and a $10M undrawn chairman line of credit funding planned operations only through June 2027.

  • Chairman Debt Conversion Cuts Liabilities

    On July 31, 2026, Richard Uihlein converted $91.0M of principal plus $14.8M of accrued interest into 34,376,167 shares at a blended ~$3.07 per share, dropping total liabilities to $46.4M from $145.7M at December 31, 2025.

  • Loss Narrows as R&D Falls

    Nine-month net loss was $17.7M versus $25.3M a year earlier, as R&D fell to $5.9M from $12.4M following completion of the NAVIGATE trial; Q3 net loss was $3.5M.

  • Material Weakness Reaffirmed

    Disclosure controls were concluded not effective as of September 30, 2026 due to a previously disclosed material weakness over the valuation of derivative liabilities tied to contingent interest on convertible notes.


Analysis · GALT · Life Sciences

The headline is a first-time substantial-doubt going-concern statement: $11.7M of cash plus a $10M undrawn chairman line of credit funds planned operations only through June 2027, and the company has no revenue and no funded trial beyond the Phase 3 protocol filed in Q3. The offset is the July 31 conversion of $105.8M of chairman debt into 34,376,167 shares, which wiped out nearly all liabilities (total liabilities fell to $46.4M from $145.7M), cut interest expense, and left a $35.2M stockholders' deficit instead of $127.9M. Existing holders should weigh that cleanup against the fact that Mr. Uihlein now controls roughly 44.3% of voting power and the company still must raise cash to start Phase 3.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GALT was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $307.6M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $3.10 info
Change: -$0.840 (-21%) info
Market Cap: $307.591M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $3.10 info
Change: -$0.815 (-21%) info
Market Cap: $307.591M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.10 info
Change: -$0.350 (-10%) info
Market Cap: $307.591M info
GALT
Aug 14, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $3.10 info
Change: -$0.390 (-11%) info
Market Cap: $307.591M info
GALT
Aug 04, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.21
Real-time Price: $3.10 info
Change: -$0.110 (-3%) info
Market Cap: $307.591M info